Table 3.
Crude incidence rate of KSHV per 100 child-months since time of enrollment in a longitudinal cohort of 287 children from Lusaka, Zambia, 2009–2012*
| Characteristic | No. of children | KSHV-positive children | % | KSHV-free child-months | Incidence rate per 100 child-months | IRR (95% CI) |
|---|---|---|---|---|---|---|
| Total | 287 | 151 | 52.6 | 3552 | 4.25 | - - |
| Mother ART | ||||||
| Never | 126 | 71 | 56.3 | 1431 | 4.96 | Ref. |
| Ever | 161 | 80 | 49.7 | 2120 | 3.77 | 0.76 (0.55 to 1.05) |
| Child HIV status | ||||||
| Negative | 196 | 100 | 51.0 | 2512 | 3.98 | Ref. |
| Positive | 91 | 51 | 56.0 | 1040 | 4.90 | 1.23 (0.88 to 1.73) |
| Child HIV/ART status | ||||||
| HIV(-) | 196 | 100 | 51.0 | 2512 | 3.98 | Ref. |
| HIV(+)/ART(+) | 74 | 39 | 52.7 | 989.6 | 3.94 | 0.99 (0.68 to 1.43) |
| HIV(+)/ART(-) | 17 | 12 | 70.6 | 50.47 | 23.78 | 5.97 (3.13 to 11.41) |
* ART = antiretroviral therapy; CI = confidence interval; HIV = human immunodeficiency virus; IRR = incidence rate ratio; KSHV = Kaposi’s sarcoma–associated herpesvirus.